



WAMA Diagnostics (Switzerland) is dedicated to developing innovative in vitro diagnostic tests. We focus on the development of multiplex immunoassays and our current project is to combine the screening of transfusion-transmissible infections in a single test. This planar multiplex chemiluminescence-based assay includes the detection of specific antibodies against HIV-1&2, HCV, HBc, Syphilis, HTLV-I/II and Chagas and the detection of antigens HIV-1 p24 and HBsAg.

We look for investors to support final steps of product development and validation, partners that could evaluate this assay for diagnostic purposes, and IVD companies interested to out-license this technology.